Biotech News
Biotechnology
UK pharma major GSK today announced it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences, a privately held biotechnology company. 15 September 2026
Biotechnology
German biotech company BioNTech and its US partner OncoC4 have put a firm number on a survival benefit they had been describing in general terms for more than a year, reporting mature overall survival (OS) data from the first stage of their Phase III lung cancer trial. 14 September 2026
Biotechnology
US pharma major AbbVie announced positive top-line results from the Phase III LUNA study, which evaluated Qulipta (atogepant), a calcitonin gene-related peptide (CGRP) receptor antagonist, for the preventive treatment of menstrual migraine in adults. 11 September 2026
Most Read
Recent news
Biotechnology
UK precision oncology company Vivan Therapeutics and Ad Atomica, the London-based AI-native drug discovery firm, have announced a discovery collaboration. 16 September 2026
Biotechnology
Danish CNS specialist Lundbeck today announced that Japan’s Ministry of Health, Labor and Welfare (MHLW) has granted marketing authorization for Vyepti (eptinezumab) for the prevention of migraine attacks in adults, marking an important milestone for patients in Japan and for Lundbeck's continued growth in Asia. 16 September 2026
Biotechnology
US biotech Vera Therapeutics said its BAFF and APRIL inhibitor Trutakna (atacicept-vymj) met all prespecified endpoints in the final efficacy analysis of the Phase III ORIGIN 3 trial in adults with primary IgA nephropathy (IgAN) at risk of disease progression, with two years of follow-up data. 16 September 2026
Biotechnology
California-based biotech company RegCell has closed $66 million in new funding, made up of a $44 million series A led by Playground Global and a further 3.4 billion yen ($22 million) in non-dilutive money from Japan's Agency for Medical Research and Development (AMED). The company said on Tuesday the cash will carry its regulatory T cell platform into clinical development across several autoimmune diseases. 16 September 2026
Biotechnology
UK pharma major GSK today announced it has entered an agreement to acquire a potential best-in-class trispecific T cell-engager (TCE) from Chimagen Biosciences, a privately held biotechnology company. 15 September 2026
Refine search
In Brief
Biotechnology
20 June 2026 US pharma major AbbVie is nearing an all-cash deal to acquire clinical-stage biotech Apogee Therapeutics for roughly $10.9 billion.
Biotechnology
8 June 2026 US biotech Incyte Pharma is nearing a deal for up to $2 billion to buy privately held blood disorder drug developer Star Therapeutics amid a wave of acquisitions by midsized drugmakers looking to supplement their pipelines, according to a Financial Times report.
Insights
Biotechnology
IPOs are back. The first six months of 2026 have seen a some of the biggest stock market debuts in biopharma history. With IPOs regularly topping the $200m mark, the amount of money raised in the first half of the year has eclipsed what the entire sector managed in the whole of 2025. 17 July 2026
Biotechnology
The biotech infrastructure sector has changed significantly since the biotechnology funding peak of 2021. 14 July 2026
Biotechnology
Biopharma coverage often focuses on two parts of the industry: the largest global drugmakers and the smallest venture-backed biotech companies. Between them sits a broad group of mid-sized regional companies that play an important role in how medicines are developed, manufactured, licensed and commercialized. 7 July 2026
Biotechnology
Italy-based drugmaker Alfasigma is seeking to use new Phase III data on filgotinib in axial spondyloarthritis (axSpA), to strengthen its credentials in rheumatology, as the firm pushes further into specialty care and rare diseases. 29 June 2026
Biotechnology
Some five years ago, Daiichi Sankyo made a strategic bet, explained Michael Zaiac, head of medical affairs oncology for Europe and Canada, in an interview with The Pharma Letter. 22 June 2026
Biotechnology
The radiopharmaceutical sector has remained one of biotech’s hottest areas over the past two years, attracting billions of dollars in investment, partnerships and acquisitions. But according to Leila Jaafar, chief executive of Swiss radiopharma developer Nuclidium, the debate is becoming more nuanced. 17 June 2026
Biotechnology
The microbiome sector has approved medicines on the market, but it has not yet delivered the broad therapeutic class that early investors once expected. Its current phase is more focused, with companies trying to show that gut bacteria can be developed into consistent, regulated products with clear clinical uses. 17 June 2026
Boardroom
Singapore-based biotech Hummingbird Bioscience today announced the appointment of Dr James Garner as president. Dr Garner will join Hummingbird’s leadership team and work alongside Piers Ingram, co-founder and chief executive. 15 September 2026
Privately-held US immuno-oncology firm Shennon Biotechnologies has raised $12 million in a financing round from Future Ventures, NextGen Venture Partners, Samos Investments, Atypical Ventures and Saras Capital, with participation from existing investors DCVC, Foundation Capital and AV8 Ventures. 14 September 2026
UK clinical-stage biotech Alchemab Therapeutics has appointed experienced pharma and biotech leader Dr Ben Porter-Brown as chief medical officer (CMO) to accelerate the clinical development of the company’s pipeline of highly novel antibody therapeutics. 10 September 2026
Netherlands-based Scenic Biotech, a company developing therapies that restore lysosomal function in neurodegenerative disease, has appointed Judith Walker as chief medical officer, as the firm prepares to move its lead program into the clinic in early 2027. 10 September 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze